Sinolink: Tumor mRNA vaccine overseas leaders welcome critical breakthroughs, with significant improvement in market sentiment.

Sinolink has released a research report stating that it has dismantled the industrial chain of the tumor mRNA vaccine sector into four core segments: upstream core materials, CDMO, AI technology platforms, and downstream innovative drug development for tumors. 1) The core elements of the upstream materials segment include plasmids, key enzymes, ionizable lipids, and LNP delivery systems. 2) CXO belongs to the water seller segment of the industry, which will benefit greatly from the upturn in the tumor mRNA vaccine sector, possessing strong certainty of performance realization. 3) The AI technology platform is a key tool to address the core bottlenecks in tumor mRNA vaccine development. 4) Downstream innovative pharmaceutical companies are the core driving force for industry development; currently, several innovative companies both domestically and internationally are accelerating their layout in tumor mRNA vaccines, with pipelines continuously advancing to clinical stages. Sinolink's main viewpoints are as follows: Technological Trends Tumor mRNA vaccines work by delivering mRNA that encodes tumor-specific antigens into the human body, allowing host cells to express these tumor antigens, which in turn induces the body to generate antigen-specific T cells that specifically recognize and kill tumor cells. mRNA was first discovered in 1961, and it wasn't until breakthroughs in 2005 with two core technologiesnucleotide base modification and lipid nanoparticles (LNP)that critical industry pain points were resolved, such as mRNA's susceptibility to degradation and strong immunogenicity. This propelled mRNA technology into a phase of rapid development and facilitated large-scale application during global public health events. Currently, the tumor mRNA vaccine industry is in a critical transitional phase from early-stage development to rapid growth, with major divisions in technology routes into universal and personalized approaches: universal vaccines target shared antigens in populations and support large-scale GMP production; personalized vaccines, based on tumor sequencing and HLA typing, select patient-specific neoantigens and adopt customized production models, leading to relatively longer production cycles. Each route has its pros and cons, leading to differentiated commercialization prospects. Presently, tumor mRNA vaccines can cover both "hot tumors" and "cold tumors" and target treatment for early-stage tumor patients, yielding a large potential patient population. From a clinical application perspective, the efficacy of tumor mRNA vaccines as a monotherapy is relatively limited; however, when combined with immune checkpoint inhibitors, they can relieve tumor microenvironment suppression, amplifying the T cell killing effect mediated by the vaccine, demonstrating clear synergistic value. Moreover, future combination therapies are expected to further extend to ADC, bispecific antibodies, radiotherapy, and other treatment modalities, potentially improving treatment outcomes for solid tumors. Industry Trends After peaking in 2021, global investment and financing in tumor mRNA vaccines has receded, but the number of financing events is showing marginal recovery. Internationally, clinical data is catalyzing a significant rebound in financing amounts by 2026, while domestic project approvals are accelerating, and a capital market recovery is expected to follow overseas trends. The tumor mRNA vaccine industry chain can be dissected into four major segments: upstream core materials, CDMO, AI technology platforms, and downstream innovative drug R&D. The upstream materials (plasmids, tool enzymes, ionizable lipids, LNP delivery systems) and CDMO are positioned as water sellers that will benefit fully from the industry upswing; the AI technology platform is a key lever for overcoming development bottlenecks; and downstream innovative drugs are the central DRIVE of the industry, with both domestic and foreign companies continuing to advance their pipelines to clinical stages. Additionally, the second half of 2026 to 2027 will witness a concentrated period for clinical readouts and application windows, with Moderna and Merck's personalized vaccine Intismeran autogene for melanoma adjuvant indications expected to file for BLA in 2027, and data for adjuvant indications of renal cancer and pancreatic cancer expected to be reported in the second half of 2026. BioNTech's Autogene cevumeran for colorectal cancer is anticipated to have results from a Phase II trial in 2027, while BNT113 and BNT1116 are expected to release key data in the latter half of 2026 and at WCLC, respectively. Both personalized and universal technology routes will achieve clinical validation simultaneously, and these clinical milestones will become significant catalysts for the sector. Risk Warnings Risks include underwhelming clinical results, uncertainties regarding combination therapies, risks related to unstable technologies and processes, commercialization not meeting expectations, potential patent and intellectual property disputes, and delays in regulatory approval.